UnitedHealth (UNH) Stock Price Forecast: Has Healthcare’s Biggest Comeback Still Got Room to Run?
UnitedHealth (NYSE: UNH) reports Q2 earnings before the opening bell. Here's why medical costs, Optum and guidance matter...
Quick overview
- UnitedHealth is set to report Q2 earnings, with investors focusing on medical costs and growth in its Optum unit rather than just earnings per share.
- Analysts expect revenue between $110 billion and $111 billion, with adjusted earnings projected to rise by 19% despite a slight year-over-year revenue decline.
- The company's Medical Care Ratio is anticipated to improve slightly, which could positively impact margins, while strong performance in Medicare Advantage remains a key factor.
- UnitedHealth's stock is currently testing support levels, with a bullish trend intact as long as it stays above $413.55.
UnitedHealth (NYSE: UNH) reports Q2 earnings before the opening bell. Here’s why medical costs, Optum and guidance matter more than another EPS beat. UnitedHealth Group (NYSE: UNH) is set to release its Q2 earnings report Thursday before the stock market opens, though investors aren’t just checking the box for another positive surprise. They’re hoping that UnitedHealth has finally left behind the headwinds from the past two years of elevated medical costs. The health insurer’s shares are changing hands around $416, near the highest level in 11 months.
Shares have rebounded sharply throughout 2026 and next steps now rest on if margin improvement, discipline and strong Optum growth is enough to convince investors that the turnaround is underway and will last.
The Market Already Expects Solid Earnings; What It Wants Is Confidence
The Street’s already pricing in a good result, and investors want to know if it’s enough. The Street’s calling for $110 billion to $111 billion in revenue in the quarter and $4.85 per share in adjusted earnings. While revenue will be slightly lower year over year as the insurer sheds the lower margin Medicaid business, earnings are expected to jump 19% as profitability improves. In other words, the emphasis now is less about rapid top-line growth and more about improving the quality of business, pricing discipline and operational efficiency.
The next level for investors will be management’s update. It’s likely they’ll try to maintain the elevated, and already high, 2026 guidance of above $18.25 for the full-year adjusted earnings, which would mean they don’t see any slowdown in the second half of the year.
Has UnitedHealth Finally Solved Its Biggest Problem?
For much of the last two years, the main metric investors were fixated on was the company’s Medical Care Ratio (MCR), the percentage of premium dollars that go directly to medical claims. Higher medical service usage sent costs for many insurers spiraling.
Analysts think UnitedHealth’s MCR for the quarter will come in at 88.6%, down from 89.4% a year ago. This is by no means a huge improvement, but even tiny changes can make a massive difference at a company the size of UnitedHealth when it comes to margins.
And there’s one other bright spot: the company’s strong Optum unit. Operating income at Optum is forecast to jump nearly 8% with growth coming from the Optum Health and Optum Rx platforms, and UnitedHealthcare’s own insurance operations continue to see benefit from better pricing and cost control.
Investors Are Also Watching Washington
Strong operating performance is only part of the story. UnitedHealth continues to see strong gains from its dominance in Medicare Advantage. A number of millions of people with UnitedHealth coverage remain enrolled in plans that will receive the highly-rated plans in government bonus payments. Additionally, the company has reduced costs and other burdens by divesting its Optum UK unit.
At the same time, there’s always regulatory risk. It’s not just the Justice Department investigation into UnitedHealth, but many healthcare insurers that are under scrutiny for reimbursement and other activities.
UnitedHealth (UNH) Stock Forecast: Rising Channel Support Faces Key Test
UnitedHealth (UNH) stock price sits at $415.92 on the 4-Hour timeframe. Price pulled back from a higher level to revisit support at the bottom of a well-defined, ongoing rising channel. Price fell short of the 50-period exponential moving average at $421.99, but stayed above channel support which sits at $413.55.
The pullback is driving RSI back to 39, a sign that momentum is losing strength, but is not yet in oversold zone. A bounce back to the upside could propel price up to $423.19. Resistance sits just ahead at $432.82. If the move continues higher, the upper boundary of the ascending channel near $439.34 is an area for bulls to look towards next.
The breakdown to $413.55 would invalidate the bullish view. If a clear reversal down from support is followed, a target for price falls to $406.43. Another downside level is $399.51. The bullish trend remains intact as long as UNH holds the ascending channel. $413.55 is the key level for bulls to defend. Holding above that level would open up $423 to $433 again.
- Check out our free forex signals
- Follow the top economic events on FX Leaders economic calendar
- Trade better, discover more Forex Trading Strategies
- Open a FREE Trading Account
- Read our latest reviews on: Avatrade, Exness, HFM and XM
Related Articles
Sidebar rates
Related Posts
Save